Titlebook: Neuroendocrine Tumors in Real Life; From Practice to Kno Annamaria Colao,Antongiulio Faggiano,Wouter de Her Book 2018 Springer Internationa

cherub

書目名稱Neuroendocrine Tumors in Real Life影響因子(影響力)




書目名稱Neuroendocrine Tumors in Real Life影響因子(影響力)學(xué)科排名




書目名稱Neuroendocrine Tumors in Real Life網(wǎng)絡(luò)公開度




書目名稱Neuroendocrine Tumors in Real Life網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Neuroendocrine Tumors in Real Life被引頻次




書目名稱Neuroendocrine Tumors in Real Life被引頻次學(xué)科排名




書目名稱Neuroendocrine Tumors in Real Life年度引用




書目名稱Neuroendocrine Tumors in Real Life年度引用學(xué)科排名




書目名稱Neuroendocrine Tumors in Real Life讀者反饋




書目名稱Neuroendocrine Tumors in Real Life讀者反饋學(xué)科排名

notification

tangle

Tumor Detection in Syndromic NET: Zollinger-Ellison Syndrome ZES was hypothesized on the basis of early age of onset and the evidence of multifocal tumors within the pancreas and duodenum, despite the absence of primary hyperparathyroidism. The diagnostic workup included endoscopic ultrasound, contrast-enhanced multi-detector computed tomography, and somatostatin-receptor scintigraphy.

gene-therapy

commute

Tumor Staging: Bronchi systemic lymphadenectomy should be performed. Postoperative long-term clinical and radiological follow-up is mandatory, especially in case of biologically aggressive tumoral forms: local relapses or distant metastases are, in fact, reported even many years after the first operation.

珊瑚

Anecdote

PARA

Prognostic Factors: Molecular Pathway – Oncogene (mTOR)nning the best therapeutic approach. Recently, the mammalian target of rapamycin (mTOR) pathway has emerged as an important therapeutic target for the medical treatment of NEN. We here review the available information on the prognostic value of mTOR pathway derangements in patients with NET.

lavish

Prognostic Factors: Molecular Pathway – Tumour Suppressor Gene (MEN1)rather than evidence-based guidelines have been developed to optimize early tumour detection and management, but open issues remain. Yet, the follow-up of MEN1 patients in real life remains challenging, especially in young patients (<20 year), in whom there is increasing evidence of asymptomatic NETs.

Arable